echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Qilu wins 1 billion injection of recombinant human follicle stimulating hormone injection

    Qilu wins 1 billion injection of recombinant human follicle stimulating hormone injection

    • Last Update: 2021-12-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    A few days ago, the official website of the State Food and Drug Administration showed that Qilu Pharmaceutical's recombinant human follicle stimulating hormone for injection was approved for marketing.
    Since the beginning of this year, Qilu Pharmaceutical has approved 7 injections
    .
    According to data from Meinenet, the sales of terminal recombinant human follicle stimulating hormone injections in China's public medical institutions have exceeded 1 billion yuan in recent years, with a year-on-year growth of 62.
    91% in the first half of 2021
    .
     
    Sales of terminal recombinant human follicle stimulating hormone injections in Chinese public medical institutions in recent years (unit: 100 million yuan)
    Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern
     
    Recombinant human follicle stimulating hormone for injection is used to treat infertility
    .
    According to data from Menet.
    com, in recent years , the sales of terminal recombinant human follicle stimulating hormone injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have all exceeded 1 billion yuan.
    An increase of 62.
    91%
    .
    Prior to this, the only manufacturers of recombinant human follicle stimulating hormone for injection were Merck and Changchun Jinsai Pharmaceutical
    .
     
      Qilu Pharmaceutical said that the recombinant human follicle stimulating hormone for injection is a blockbuster product that has been researched for 11 years.
    The approval of the market this time will further increase the availability of the drug and bring high-quality domestic drugs to patients
    .
     
     
     Source: Meinenet MED2.
    0 Chinese Drug Evaluation Database
     
      Since the beginning of this year, Qilu Pharmaceutical has approved 7 injections, among which, Ceftazidime Avibactam Sodium for injection won the first imitation in China
    .
    From the perspective of the treatment field (big category), it covers systemic anti-infective drugs, anti- tumor and immunomodulators, genitourinary system and sex hormone drugs, cardiovascular system drugs, digestive system and metabolic drugs
    .
     
      Source: official website of the State Food and Drug Administration, Mi Nei.
    com database, etc.
      A few days ago, the official website of the State Food and Drug Administration showed that Qilu Pharmaceutical's recombinant human follicle stimulating hormone for injection was approved for marketing.
    Since the beginning of this year, Qilu Pharmaceutical has approved 7 injections
    .
    According to data from Meinenet, the sales of terminal recombinant human follicle stimulating hormone injections in China's public medical institutions have exceeded 1 billion yuan in recent years, with a year-on-year growth of 62.
    91% in the first half of 2021
    .
     
      Sales of terminal recombinant human follicle stimulating hormone injections in Chinese public medical institutions in recent years (unit: 100 million yuan)
      Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern
     
      Recombinant human follicle stimulating hormone for injection is used to treat infertility
    .
    According to data from Menet.
    com, in recent years , the sales of terminal recombinant human follicle stimulating hormone injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have all exceeded 1 billion yuan.
    An increase of 62.
    91%
    .
    Prior to this, the only manufacturers of recombinant human follicle stimulating hormone for injection were Merck and Changchun Jinsai Pharmaceutical
    .
     
      Qilu Pharmaceutical said that the recombinant human follicle stimulating hormone for injection is a blockbuster product that has been researched for 11 years.
    The approval of the market this time will further increase the availability of the drug and bring high-quality domestic drugs to patients
    .
     
     
     Source: Meinenet MED2.
    0 Chinese Drug Evaluation Database
     
      Since the beginning of this year, Qilu Pharmaceutical has approved 7 injections, among which, Ceftazidime Avibactam Sodium for injection won the first imitation in China
    .
    From the perspective of the treatment field (big category), it covers systemic anti-infective drugs, anti- tumor and immunomodulators, genitourinary system and sex hormone drugs, cardiovascular system drugs, digestive system and metabolic drugs
    .
     
      Source: official website of the State Food and Drug Administration, Mi Nei.
    com database, etc.
      A few days ago, the official website of the State Food and Drug Administration showed that Qilu Pharmaceutical's recombinant human follicle stimulating hormone for injection was approved for marketing.
    Since the beginning of this year, Qilu Pharmaceutical has approved 7 injections
    .
    According to data from Meinenet, the sales of terminal recombinant human follicle stimulating hormone injections in China's public medical institutions have exceeded 1 billion yuan in recent years, with a year-on-year growth of 62.
    91% in the first half of 2021
    .
     
      Sales of terminal recombinant human follicle stimulating hormone injections in Chinese public medical institutions in recent years (unit: 100 million yuan)
      Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern
     
      Recombinant human follicle stimulating hormone for injection is used to treat infertility
    .
    According to data from Menet.
    com, in recent years , the sales of terminal recombinant human follicle stimulating hormone injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have all exceeded 1 billion yuan.
    An increase of 62.
    91%
    .
    Prior to this, the only manufacturers of recombinant human follicle stimulating hormone for injection were Merck and Changchun Jinsai Pharmaceutical
    .
    Hospital hospital hospital
     
      Qilu Pharmaceutical said that the recombinant human follicle stimulating hormone for injection is a blockbuster product that has been researched for 11 years.
    The approval of the market this time will further increase the availability of the drug and bring high-quality domestic drugs to patients
    .
     
     
     
     Source: Meinenet MED2.
    0 Chinese Drug Evaluation Database
     
      Since the beginning of this year, Qilu Pharmaceutical has approved 7 injections, among which, Ceftazidime Avibactam Sodium for injection won the first imitation in China
    .
    From the perspective of the treatment field (big category), it covers systemic anti-infective drugs, anti- tumor and immunomodulators, genitourinary system and sex hormone drugs, cardiovascular system drugs, digestive system and metabolic drugs
    .
    Tumor tumor tumor
     
      Source: official website of the State Food and Drug Administration, Mi Nei.
    com database, etc.
      
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.